BAFF regulates activation of self-reactive T cells through B-cell dependent mechanisms and mediates protection in NOD mice

European Journal of Immunology

Volumn 44, Issue 4, 2014, Pages 983-993

  Mariño, Eliana ^a,b   Walters, Stacey N ^a   Villanueva, Jeanette E ^a   Richards, James L ^b   Mackay, Charles R ^b   Grey, Shane T ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

BAFF; Diabetes; Islet allograft; NOD mice; Self reactive T cells

Indexed keywords

AUTOANTIGEN; B CELL ACTIVATING FACTOR; BRIOBACEPT; CYCLOPHOSPHAMIDE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; IMMUNOGLOBULIN M;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CELL EXPANSION; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; IMMUNOPHENOTYPING; INSULITIS; KIDNEY CAPSULE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTECTION; SKIN ALLOGRAFT; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

BAFF; DIABETES; ISLET ALLOGRAFT; NOD MICE; SELF-REACTIVE T CELLS;

ANIMALS; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; FEMALE; FLOW CYTOMETRY; GLUCOSE-6-PHOSPHATASE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOPHENOTYPING; ISLETS OF LANGERHANS TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; T-LYMPHOCYTES; TIME FACTORS;

EID: 84897976554     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201344186     Document Type: Article

References (56)

1. Mackay, F., Woodcock, S. A., Lawton, P., Ambrose, C., Baetscher, M., Schneider, P., Tschopp, J. et al., Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 1999. 190: 1697-1710.
2. Groom, J., Kalled, S. L., Cutler, A. H., Olson, C., Woodcock, S. A., Schneider, P., Tschopp, J. et al., Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 2002. 109: 59-68.
3. Cheema, G. S., Roschke, V., Hilbert, D. M. and Stohl, W., Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001. 44: 1313-1319.
4. Stohl, W., B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr. Rheumatol. Rep. 2002. 4: 345-350.
5. Tan, S. M., Xu, D., Roschke, V., Perry, J. W., Arkfeld, D. G., Ehresmann, G. R., Migone, T. S. et al., Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003. 48: 982-992.
6. Thien, M., Phan, T. G., Gardam, S., Amesbury, M., Basten, A., Mackay, F. and Brink, R., Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004. 20: 785-798.
7. Batten, M., Groom, J., Cachero, T. G., Qian, F., Schneider, P., Tschopp, J., Browning, J. L. et al., BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 2000. 192: 1453-1466.
8. Martin, F. and Kearney, J. F., Marginal-zone B cells. Nat. Rev. Immunol. 2002. 2: 323-335.
9. Rolf, J., Motta, V., Duarte, N., Lundholm, M., Berntman, E., Bergman, M. L., Sorokin, L., et al., The enlarged population of marginal zone/CD1d(high) B lymphocytes in nonobese diabetic mice maps to diabetes susceptibility region Idd11. J. Immunol. 2005. 174: 4821-4827.
10. Marino, E., Batten, M., Groom, J., Walters, S., Liuwantara, D., Mackay, F. and Grey, S. T., Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Diabetes 2008. 57: 395-404.
11. Wellmann, U., Werner, A. and Winkler, T. H., Altered selection processes of B lymphocytes in autoimmune NZB/W mice, despite intact central tolerance against DNA. Eur. J. Immunol. 2001. 31: 2800-2810.
12. Gross, J. A., Johnston, J., Mudri, S., Enselman, R., Dillon, S. R., Madden, K., Xu, W. et al., TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000. 404: 995-999.
13. von Bulow, G. U. and Bram, R. J., NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997. 278: 138-141.
14. Thompson, J. S., Bixler, S. A., Qian, F., Vora, K., Scott, M. L., Cachero, T. G., Hession, C. et al., BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001. 293: 2108-2111.
15. Schiemann, B., Gommerman, J. L., Vora, K., Cachero, T. G., Shulga-Morskaya, S., Dobles, M., Frew, E. et al., An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001. 293: 2111-2114.
16. Ramanujam, M., Wang, X., Huang, W., Liu, Z., Schiffer, L., Tao, H., Frank, D. et al., Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J. Clin. Invest. 2006. 116: 724-734.
17. Ding, C., Foote, S. and Jones, G., B-cell-targeted therapy for systemic lupus erythematosus: an update. BioDrugs 2008. 22: 239-249.
18. Navarra, S. V., Guzman, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K. et al., Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011. 377: 721-731.
19. Ramanujam, M. and Davidson, A., The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res. Ther. 2004. 6: 197-202.
20. Marino, E., Silveira, P. A., Stolp, J. and Grey, S. T., B cell-directed therapies in type 1 diabetes. Trends Immunol. 2011. 32: 287-294.
21. Marino, E., Villanueva, J., Walters, S., Liuwantara, D., Mackay, F. and Grey, S. T., CD4(+)CD25(+) T-cells control autoimmunity in the absence of B-cells. Diabetes 2009. 58: 1568-1577.
22. Zekavat, G., Rostami, S. Y., Badkerhanian, A., Parsons, R. F., Koeberlein, B., Yu, M., Ward, C. D. et al., In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J. Immunol. 2008. 181: 8133-8144.
23. Silveira, P. A. and Grey, S. T., B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol. Metab. 2006. 17: 128-135.
24. Serreze, D. V., Chapman, H. D., Varnum, D. S., Hanson, M. S., Reifsnyder, P. C., Richard, S. D., Fleming, S. A. et al., B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J. Exp. Med. 1996. 184: 2049-2053.
25. Hu, C. Y., Rodriguez-Pinto, D., Du, W., Ahuja, A., Henegariu, O., Wong, F. S., Shlomchik, M. J. et al., Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 2007. 117: 3857-3867.
26. Ng, L. G., Sutherland, A. P., Newton, R., Qian, F., Cachero, T. G., Scott, M. L., Thompson, J. S. et al., B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol. 2004. 173: 807-817.
27. Ye, Q., Wang, L., Wells, A. D., Tao, R., Han, R., Davidson, A., Scott, M. L. et al., BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur. J. Immunol. 2004. 34: 2750-2759.
28. Yu, G., Boone, T., Delaney, J., Hawkins, N., Kelley, M., Ramakrishnan, M., McCabe, S. et al., APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol. 2000. 1: 252-256.
29. Huard, B., Arlettaz, L., Ambrose, C., Kindler, V., Mauri, D., Roosnek, E., Tschopp, J. et al., BAFF production by antigen-presenting cells provides T cell co-stimulation. Int. Immunol. 2004. 16: 467-475.
30. Makhlouf, L., Grey, S. T., Dong, V., Csizmadia, E., Arvelo, M. B., Auchincloss, H., Jr., Ferran, C. et al., Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation 2004. 77: 990-997.
31. Harada, M. and Makino, S., Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia 1984. 27: 604-606.
32. Greeley, S. A., Moore, D. J., Noorchashm, H., Noto, L. E., Rostami, S. Y., Schlachterman, A., Song, H. K. et al., Impaired activation of islet-reactive CD4 T cells in pancreatic lymph nodes of B cell-deficient nonobese diabetic mice. J. Immunol. 2001. 167: 4351-4357.
33. Santamaria, P., Utsugi, T., Park, B. J., Averill, N., Kawazu, S. and Yoon, J. W., Beta-cell-cytotoxic CD8+ T cells from nonobese diabetic mice use highly homologous T cell receptor alpha-chain CDR3 sequences. J. Immunol. 1995. 154: 2494-2503.
34. Han, B., Serra, P., Yamanouchi, J., Amrani, A., Elliott, J. F., Dickie, P., Dilorenzo, T. P. et al., Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes. J. Clin. Invest. 2005. 115: 1879-1887.
35. Brodie, G. M., Wallberg, M., Santamaria, P., Wong, F. S. and Green, E. A., B Cells Promote Intra-Islet CD8 +Cytotoxic T Lymphocyte Survival To Enhance Type 1 Diabetes. Diabetes 2008.
36. Marino, E., Tan, B., Binge, L., Mackay, C. R. and Grey, S. T., B-Cell Cross-Presentation of Autologous Antigen Precipitates Diabetes. Diabetes 2012.
37. Marino, E. and Grey, S. T., A new role for an old player: Do B cells unleash the self-reactive CD8+ T cell storm necessary for the development of type 1 diabetes? J. Autoimmun. 2008. 31: 301-305.
38. Serreze, D. V., Fleming, S. A., Chapman, H. D., Richard, S. D., Leiter, E. H. and Tisch, R. M., B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J. Immunol. 1998. 161: 3912-3918.
39. Marino, E., Tan, B., Binge, L., Mackay, C. R. and Grey, S. T., B-cell cross-presentation of autologous antigen precipitates diabetes. Diabetes 2012. 61: 2893-2905.
40. Chiu, P. P., Serreze, D. V. and Danska, J. S., Development and function of diabetogenic T-cells in B-cell-deficient nonobese diabetic mice. Diabetes 2001. 50: 763-770.
41. Holz, A., Dyrberg, T., Hagopian, W., Homann, D., von Herrath, M. and Oldstone, M. B., Neither B lymphocytes nor antibodies directed against self antigens of the islets of Langerhans are required for development of virus-induced autoimmune diabetes. J. Immunol. 2000. 165: 5945-5953.
42. Yamanouchi, J., Puertas, M. C., Verdaguer, J., Lyons, P. A., Rainbow, D. B., Chamberlain, G., Hunter, K. M. et al., Idd9.1 locus controls the suppressive activity of FoxP3+CD4+CD25+ regulatory T-cells. Diabetes 2010. 59: 272-281.
43. Nagata, M., Santamaria, P., Kawamura, T., Utsugi, T. and Yoon, J. W., Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice. J. Immunol. 1994. 152: 2042-2050.
44. Amrani, A., Verdaguer, J., Anderson, B., Utsugi, T., Bou, S. and Santamaria, P., Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice. J. Clin. Invest. 1999. 103: 1201-1209.
45. Graser, R. T., DiLorenzo, T. P., Wang, F., Christianson, G. J., Chapman, H. D., Roopenian, D. C., Nathenson, S. G. et al., Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. J. Immunol. 2000. 164: 3913-3918.
46. Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A. et al., Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009. 361: 2143-2152.
47. Martin, S., Wolf-Eichbaum, D., Duinkerken, G., Scherbaum, W. A., Kolb, H., Noordzij, J. G. and Roep, B. O., Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N. Engl. J. Med. 2001. 345: 1036-1040.
48. O'Connell, P., Holmes-Walker, D., Goodman, D., Hawthorne, W., Grey, S., Drogemuller, C., Ward, G. et al., Multicenter australian trial of islet transplantation: improving accessibility and outcomes. Am. J. Transplant. 2013. 13: 1850-1858.
49. Parsons, R. F., Yu, M., Vivek, K., Zekavat, G., Rostami, S. Y., Ziaie, A. S., Luo, Y. et al., Murine Islet Allograft Tolerance Upon Blockade of the B-Lymphocyte Stimulator, BLyS/BAFF. Transplantation 2012. 93: 676-685.
50. Liu, C., Noorchashm, H., Sutter, J. A., Naji, M., Prak, E. L., Boyer, J., Green, T. et al., B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat. Med. 2007. 13: 1295-1298.
51. Epstein, M. M., Di Rosa, F., Jankovic, D., Sher, A. and Matzinger, P., Successful T cell priming in B cell-deficient mice. J. Exp. Med. 1995. 182: 915-922.
52. Chatenoud, L., Ferran, C., Legendre, C., Thouard, I., Merite, S., Reuter, A., Gevaert, Y. et al., In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990. 49: 697-702.
53. Witherspoon, R. P., Deeg, H. J. and Storb, R., Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplant Sci. 1994. 4: 33-41.
54. Serreze, D. V., Chapman, H. D., Niens, M., Dunn, R., Kehry, M. R., Driver, J. P., Haller, M. et al., Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. Diabetes 2011. 60: 2914-2921.
55. Pelletier, M., Thompson, J. S., Qian, F., Bixler, S. A., Gong, D., Cachero, T., Gilbride, K. et al., Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J. Biol. Chem. 2003. 278: 33127-33133.
56. Grey, S. T., Longo, C., Shukri, T., Patel, V. I., Csizmadia, E., Daniel, S., Arvelo, M. B. et al., Genetic engineering of a suboptimal islet graft with A20 preserves beta cell mass and function. J. Immunol. 2003. 170: 6250-6256.